Compare OPEN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPEN | IBRX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | N/A | N/A |
| Metric | OPEN | IBRX |
|---|---|---|
| Price | $5.06 | $6.09 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.67 | ★ $11.80 |
| AVG Volume (30 Days) | ★ 61.6M | 52.8M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,719,000,000.00 | $82,555,000.00 |
| Revenue This Year | N/A | $680.06 |
| Revenue Next Year | $22.96 | $90.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1025.95 |
| 52 Week Low | $0.51 | $1.83 |
| 52 Week High | $10.87 | $8.28 |
| Indicator | OPEN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 66.95 |
| Support Level | $6.26 | $5.67 |
| Resistance Level | $6.79 | $6.75 |
| Average True Range (ATR) | 0.37 | 0.88 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 11.97 | 59.14 |
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.